2. Search Result
Search Result
Results for "

electrophysiology

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100952
    Nifenalol hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Nifenalol hydrochloride is a β-adrenergic receptor antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure .
    Nifenalol hydrochloride
  • HY-105454
    Recainam

    Wy-42362

    		 Others Cardiovascular Disease
    Recainam (Wy-42362) is an orally active anti-arrhythmic agent with Class I electrophysiological properties. Recainam suppresses complex ventricular arrhythmias. Racainam exhibits a good pharmacokinetic character in Sprague Dawley rats .
    Recainam
  • HY-19679
    Quinacainol

    PK 10139

    		 Others Cardiovascular Disease
    Quinacainol is a Class I antiarrhythmic drug with antiarrhythmic activity. Quinacainol improves arrhythmias by affecting the electrophysiological properties of the heart. Quinacainol is 5 to 10 times more effective for arrhythmia than Quinidine (HY-150123). Quinacainol can be used to study cardiac electrophysiology .
    Quinacainol
  • HY-132201
    MK-8153

    		Potassium Channel Metabolic Disease
    MK-8153 is a potent, selective and orally active inhibitor of renal outer medullary potassium channel (ROMK), with IC50s of 5 nM, 34 μM for ROMK electrophysiology (EP) and hERG EP, respectively. MK-8153 can be used as the diuretic/atriuretic .
    MK-8153
  • HY-108760
    Gadoterate meglumine

    Gd-DOTA; Magnescope; P-449

    		 Biochemical Assay Reagents Cardiovascular Disease Others Neurological Disease
    Gadoterate meglumine (Gd-DOTA; P-449) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine paramagnetics in MRI can change the uniformity of the local magnetic field, resulting in a shorter relaxation time for neighboring protons. Gadoterate meglumine's gadoterate ions combine with the ligand DOTA (1,4,7, 10-Tetraazacyclododecane-N,N',N ",N "-tetraacetic acid) to form a stable complex. This stability helps prevent gadolinium ions from dissociating from the complex, thereby reducing potential toxicity. Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology .
    Gadoterate meglumine
  • HY-105454A
    Recainam hydrochloride

    Wy-42362 hydrochloride

    		 Others Cardiovascular Disease
    Recainam (Wy-42362) hydrochloride is an orally active anti-arrhythmic agent with Class I electrophysiological properties. Recainam suppresses complex ventricular arrhythmias. Racainam hydrochloride exhibits a good pharmacokinetic character in Sprague Dawley rats .
    Recainam hydrochloride
  • HY-B0405A
    Bupivacaine hydrochloride
    3 Publications Verification

    		 iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease Cancer
    Bupivacaine hydrochloride is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain .
    Bupivacaine hydrochloride
  • HY-B0405
    Bupivacaine
    3 Publications Verification

    		 iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease Cancer
    Bupivacaine is a NMDA receptor inhibitor. Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain .
    Bupivacaine
  • HY-B0405S
    Bupivacaine-d9

    		Isotope-Labeled Compounds iGluR Sodium Channel Calcium Channel Potassium Channel Neurological Disease
    Bupivacaine-d99 is a deuterium labeled Bupivacaine. Bupivacaine is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain[1][2][3].
    Bupivacaine-d9
  • HY-156104
    CaMKIIα-PHOTAC

    		PROTACs CaMK Neurological Disease
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .
    CaMKIIα-PHOTAC
  • HY-161062
    TAOA AM Ester trimethyl lock

    		EAAT Neurological Disease
    TAOA AM Ester trimethyl lock is a high-affinity fluorescent prodrug-like inhibitor of the excitatory amino acid transporter (EAAT). It can penetrate the cell membrane and be activated by hydrolysis by endogenous cell esterases to form active EAAT inhibitors. TAOA AM Ester trimethyl lock can be used to study neurodegeneration and neuronal cell death .
    TAOA AM Ester trimethyl lock
  • HY-122560A
    VU0134992 hydrochloride
    3 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992 hydrochloride
  • HY-122560
    VU0134992

    		Potassium Channel Cardiovascular Disease
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: